Eli Lilly and Company (NYSE: LLY), a United States-based pharmaceutical company, announced on Friday that it is planning to construct a new high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany.

The facility requires an investment of USD2.5bn and will further expand the firm's global parenteral (injectable) product and device manufacturing network and support an increased demand for the company's medicines, including its diabetes and obesity portfolio.

With the proposed facility in Alzey, the company is to operate a total of six manufacturing sites in Europe, including one in nearby Fegersheim, France. The company's ongoing investments in Europe is intended to create operational synergies, strengthen university and government relationships, support the early-stage life science ecosystem, and diversify the increasing company's presence in Europe.